ReviewJournal of nanobiotechnology2022
Aggregation-induced emission photosensitizer-based photodynamic therapy in cancer: from chemical to clinical.
Review in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 114 citations in OpenAlex.
- Photodynamic therapy: research progress and paradigm evolution from mechanism innovation to clinical breakthrough in cancers.Medical gas research · 2026Review
- Reprogramming Photodynamic Therapy with BODIPY Photosensitizers: From Local Phototoxicity Toward Precision Photodynamic Oncology.Molecules (Basel, Switzerland) · 2026Review
- A Critical Synthesis of Natural Photosensitizers in Photodynamic Food Preservation Covering Mechanisms, Matrix-Specific Applications, and Translational Barriers.Comprehensive reviews in food science and food safety · 2026Review
- Aptamer-functionalized aggregation-induced emission micelles for integrated detection and photodegradation of lipopolysaccharides.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Review
- Mechano-Organ-on-Chip for Cancer Research.International journal of molecular sciences · 2026Review
- Recent Advances in Nanomedicine for Targeted Phototherapy in Head and Neck Cancer.International journal of nanomedicine · 2026Review
- Metal-based nanomaterials for cancer phototherapy: current advancements and translational challenges.Frontiers in pharmacology · 2026Review
- A viscosity-activable nano-micelle with aggregation-induced emission for boosting NIR-II fluorescence imaging-guided synergetic photodynamic/photothermal therapy of breast cancer.Materials today. Bio · 2025Article
- Fluorescent Albumin-BindingInternational journal of molecular sciences · 2025Article
- Strategic Design of Aptamer-Guided Aggregation-Induced Emission Nanoparticles for Targeted Photodynamic Therapy in Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Supramolecular Aggregation-Induced Emission Photosensitizer Encapsulated by Cucurbit[8]uril Nanocavity Boosts Hypoxia-Activated Tumor Therapy.ACS applied nano materials · 2025Article
- Programmed Aggregation of Lipidated Nitrobenzoselenadiazole as a Photo-Activatable Pyroptosis Inducer.Advanced healthcare materials · 2025Article
- Recent advances in phototherapy-based nanomedicine of lymphoma.Materials today. Bio · 2025Review
- Next-generation Nanomaterial-based phototherapeutic strategies for tumor: from NIR responsiveness to smart activation.Nanomedicine (London, England) · 2025Review
- Fluorescent Antibiotics: Bridging Diagnostic and Therapy in the Fight against Bacterial Infections.Small science · 2025Review
- Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy.Journal of hematology & oncology · 2025Review
- Activatable Photosensitizers: From Fundamental Principles to Advanced Designs.Angewandte Chemie (International ed. in English) · 2025Review
- Recent Advances in Strategies to Enhance Photodynamic and Photothermal Therapy Performance of Single-Component Organic Phototherapeutic Agents.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches.Exploration of targeted anti-tumor therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Cancer remains a serious threat to human health owing to the lack of effective treatments. Photodynamic therapy (PDT) has emerged as a promising non-invasive cancer treatment that consists of three main elements: photosensitizers (PSs), light and oxygen. However, some traditional PSs are prone to aggregation-caused quenching (ACQ), leading to reduced reactive oxygen species (ROS) generation capacity. Aggregation-induced emission (AIE)-PSs, due to their distorted structure, suppress the strong molecular interactions, making them more photosensitive in the aggregated state instead. Activated by light, they can efficiently produce ROS and induce cell death. PS is one of the core factors of efficient PDT, so proceeding from the design and preparation of AIE-PSs, including how to manipulate the electron donor (D) and receptor (A) in the PSs configuration, introduce heavy atoms or metal complexes, design of Type I AIE-PSs, polymerization-enhanced photosensitization and nano-engineering approaches. Then, the preclinical experiments of AIE-PSs in treating different types of tumors, such as ovarian cancer, cervical cancer, lung cancer, breast cancer, and its great potential clinical applications are discussed. In addition, some perspectives on the further development of AIE-PSs are presented. This review hopes to stimulate the interest of researchers in different fields such as chemistry, materials science, biology, and medicine, and promote the clinical translation of AIE-PSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.